Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797980 | 0.95 | POLB (0.38) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL6799070 | 0.86 | POLB (0.41) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL6799072 | 0.86 | GAA (0.41) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL7877960 | 0.85 | HPGD (0.45) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL6798204 | 0.82 | KDM4E (0.35) | KDM4EALDH1A1HPGDALOX5PGR | |
| SCHEMBL6798564 | 0.82 | LDHA (0.36) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL6796884 | 0.82 | AGER (0.40) | POLBGAAMAOAKDM4EALDH1A1 | |
| SCHEMBL6798688 | 0.81 | PLA2G2A (0.34) | POLBPLA2G2AKDM4EALDH1A1MCL1 | |
| SCHEMBL6797518 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1HPGDALOX5SMN1; SMN2 | |
| SCHEMBL7873290 | 0.80 | DYRK1A (0.43) | POLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | POLB 1536/4885GAA 292/4885MAOA 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.